PRJ2215: Assessment of Bupropion Misuse/Abuse 2004-2011 (201235)

Study identification

• EU PAS number:
  EUPAS5568
• Study ID:
  48174
• Official title and acronym:
  PRJ2215: Assessment of Bupropion Misuse/Abuse 2004-2011 (201235)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The objective of this study is to examine the degree of misuse and abuse of bupropion using the Drug Abuse Warning Network Database. Objectives are as follows: 1. To examine the number of bupropion reports over time within the DAWN database and to draw a comparison against the number of all DAWN reports for prescription drugs. 2. To examine the number of reports for bupropion, stratified by demographics, route of administration, and disposition of the patient.
• Study status:
  Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned:03/12/2013

Actual:03/12/2013

Study start date

Planned:03/12/2013

Actual:22/11/2013

Data analysis start date

Planned:03/12/2013

Actual:03/12/2013

Date of final study report

Planned:31/03/2014

Actual:16/06/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)